The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group - PubMed (original) (raw)

PMID: 2869996

Clinical Trial

The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group

No authors listed. Diabetes. 1986 May.

Abstract

The Diabetes Control and Complications Trial (DCCT) is a randomized, controlled clinical trial designed to assess the relationship between glycemic control and the development, progression, or amelioration of early vascular complications in persons with insulin-dependent diabetes mellitus (IDDM). The DCCT consists of two parallel studies: a primary prevention study and a secondary intervention study. The principal outcome in the primary prevention study is the initial appearance and subsequent progression of background retinopathy. In the secondary intervention study, the principal outcome is the progression or amelioration of preexistent minimal retinopathy. Subjects are randomly assigned to receive either experimental or standard therapy. Experimental therapy involves the use of an intensive insulin regimen designed to maintain near-normal glycemic levels in the absence of severe hypoglycemia. Standard treatment is designed to maintain near-normal glycemic levels in the absence of severe hypoglycemia. Standard treatment is designed to maintain subjects free of clinical symptoms related to hyper- or hypoglycemia while receiving up to two insulin injections daily. Two hundred seventy-eight volunteers have been enrolled in 21 centers in the United States and Canada in a preliminary study to assess the feasibility of conducting a full-scale, long-term clinical trial. Based on an external review of the feasibility study results, the DCCT will be expanded to include over 1400 subjects treated for a period of up to 10 yr. This article describes the DCCT and the considerations that led to the choice of specific design features for the feasibility phase.

PubMed Disclaimer

Cited by

Association between personality factors and health-related quality of life in type 1 diabetes patients.
de Barreiros Gavazza MLN, Martins E Netto, Ramalho ACR. de Barreiros Gavazza MLN, et al. Arch Endocrinol Metab. 2022 Nov 17;66(6):792-799. doi: 10.20945/2359-3997000000524. Epub 2022 Oct 11. Arch Endocrinol Metab. 2022. PMID: 36219199 Free PMC article.
Electrooxidation of Phenol on Polyelectrolyte Modified Carbon Electrodes for Use in Insulin Pump Infusion Sets.
Zhou L, Huber DE, van Antwerp B, Pennathur S. Zhou L, et al. J Diabetes Sci Technol. 2024 May;18(3):625-634. doi: 10.1177/19322968221123083. Epub 2022 Sep 13. J Diabetes Sci Technol. 2024. PMID: 36112811 Free PMC article.
Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study.
Al-Kateb H, Boright AP, Mirea L, Xie X, Sutradhar R, Mowjoodi A, Bharaj B, Liu M, Bucksa JM, Arends VL, Steffes MW, Cleary PA, Sun W, Lachin JM, Thorner PS, Ho M, McKnight AJ, Maxwell AP, Savage DA, Kidd KK, Kidd JR, Speed WC, Orchard TJ, Miller RG, Sun L, Bull SB, Paterson AD; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Al-Kateb H, et al. Diabetes. 2008 Jan;57(1):218-28. doi: 10.2337/db07-1059. Epub 2007 Oct 3. Diabetes. 2008. PMID: 17914031 Free PMC article. Clinical Trial.
Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: the DCCT/EDIC Genetics Study.
Boright AP, Paterson AD, Mirea L, Bull SB, Mowjoodi A, Scherer SW, Zinman B; DCCT/EDIC Research Group. Boright AP, et al. Diabetes. 2005 Apr;54(4):1238-44. doi: 10.2337/diabetes.54.4.1238. Diabetes. 2005. PMID: 15793268 Free PMC article.
Hyperglycemia Induces Inflammatory Response of Human Macrophages to CD163-Mediated Scavenging of Hemoglobin-Haptoglobin Complexes.
Matuschik L, Riabov V, Schmuttermaier C, Sevastyanova T, Weiss C, Klüter H, Kzhyshkowska J. Matuschik L, et al. Int J Mol Sci. 2022 Jan 26;23(3):1385. doi: 10.3390/ijms23031385. Int J Mol Sci. 2022. PMID: 35163309 Free PMC article.

The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group - PubMed (original) (raw)